GH Research PLC GHRS

GHRS Company Overview

GH Research PLC is a clinical-stage biopharmaceutical company focused on developing therapies based on 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), a serotonergic psychedelic compound, for the treatment of psychiatric and neurological disorders. The company operates within the biotechnology and mental health therapeutics industries, with a primary emphasis on treatment-resistant depression (TRD) and related mood disorders. GH Research’s core development programs include proprietary formulations and delivery systems designed to administer 5-MeO-DMT in controlled clinical settings.

The company’s principal product candidates include GH001, an inhalable formulation of synthetic 5-MeO-DMT; GH002, an intravenous formulation; and GH003, an intranasal formulation. GH Research positions itself within the emerging psychedelic medicine sector by focusing on rapid-acting psychiatric therapies supported by clinical protocols and intellectual property around administration methods and formulation technologies. The company was founded in 2018 and is headquartered in Dublin, Ireland. It became publicly traded on the Nasdaq Global Market under the ticker GHRS in 2021 following its initial public offering.